UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549 ____________________

FORM 8-K

CURRENT REPORT

~~Pursuant to~~PURSUANT ~~Section~~TO SECTION 13 orOR ~~Section~~ 15(d) ~~of the Securities Exchange Act of 1934~~OF

~~Date~~THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of ~~Earliest~~earliest ~~Event~~event ~~Reported~~reported): ~~May~~June 922, 2016 Ember Therapeutics, Inc. (Exact name of registrant as specified in its charter)

EMBER THERAPEUTICS, INC.

Delaware	033-13474-NY	01-3341552
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

(Exact name of registrant as specified in its charter)

135 East 57th Street, 24th Floor

New York, NY

10022

(Address of principal executive offices)

(Zip Code)

Delaware		033-13474-NY		01-3341552
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Registrant’s telephone number, including area code: (646) 406-6243

~~135 East~~___________________________________________________ ~~57th~~(Former ~~Street~~name or former address, ~~24th~~if ~~Floor~~changed since last report)

~~New~~Check the appropriate box below if the Form 8-K filing is intended ~~York,~~to NYsimultaneously ~~10022~~satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (~~Address of~~17CFR ~~Principal~~230.425) ~~Executive~~[ ~~Offices~~] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~(646) 406~~SECTION 1-~~6243~~ REGISTRANT’S BUSINESS AND OPERATIONS

~~(Issuer’s telephone~~Item ~~number)~~1.01 Entry Into A Material Definitive Agreement

On June 22, 2016 we entered into a First Amendment to Distribution, License, and Supply Agreement (~~Previous~~the “Amendment”) with Knight Therapeutics, Inc. (“Knight”). ~~Address~~The Amendment expands the scope of ~~Principal~~our ~~Executive~~exclusive ~~Offices)~~distributorship with Knight. Under the Amendment, the field for which Knight shall act as the exclusive distributor of our products has been expanded from the limited fields of osteoarthritis, chronic kidney disease and Alport Syndrome to include all approved human use indications. Further, the licensed products for which Knight will act as our exclusive distributor has been expanded to include all of our current and future products including BMP-7, MigralexTM, and ICX-RHY/VaveltaTM. Finally, the exclusively licensed territory for Knight has been expanded to include the Caribbean and Romania, in addition to the existing territories of Canada, Israel, Russia, and Sub-Saharan Africa.

~~Check the~~Our ~~appropriate~~agreement ~~box~~with ~~below~~Knight ifotherwise ~~the~~remains as ~~Form 8-K~~set ~~filing~~forth isin ~~intended~~the toDistribution, ~~simultaneously~~License, ~~satisfy~~and ~~the~~Supply ~~filing~~Agreement ~~obligation~~filed as Exhibit 10.14 to ~~the~~our ~~registrant under~~Current ~~any~~Report ofon ~~the~~Form ~~following~~8-K ~~provisions:~~filed February 3, 2016.

☐SECTION ~~Written~~9 ~~communications~~– ~~pursuant~~Financial Statements toand ~~Rule 425 under the Securities Act (17 CFR 230.425)~~Exhibits

☐Item ~~Soliciting~~9.01 ~~material~~Financial ~~pursuant~~Statements toand ~~Rule 14a-12 under the Exchange Act (17 CFR 240~~Exhibits.~~14a-12)~~

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Exhibit No.	Description
10.1	First Amendment to Distribution, License, and Supply Agreement with Knight Therapeutics, Inc.

~~☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))~~SIGNATURES

~~Item 4.01~~Pursuant to the requirements of the Securities ~~Changes~~Exchange inAct ~~Registrant’s~~of ~~Certifying~~1934, ~~Accountant~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~On May~~Ember 9Therapeutics, ~~2016, we dismissed EisnerAmper LLP (the “Former Accountant”) as our independent auditor~~Inc. ~~Also on May 9, 2016, our board of directors appointed LJ Soldinger Associates, LLC (the “New Accountant”) as our new independent registered public accounting firm.~~

The Former Accountant was engaged on February 8, 2016. From the time of its engagement through the date of its dismissal on May 9, 2016, the services provided by the Former Accountant consisted the audit of Ember Therapeutics, Inc’/s/ ~~(“Ember”- a~~Joseph privately held company which merged into the Registrant) financial statements years ended December 31, 2014 and 2013, which financial statements contained an uncertainty paragraph with respect to Ember’s ability to continue as a going concern, and an interim review of Ember’s financial statements for the nine months ended September 30, 2015. The Former Accountant did not render an audit report on any of the Registrant’s annual financial statements because no annual report was filed by the Registrant during the time of its engagement by the Registrant.Hernandez

~~The Former~~Joseph ~~Accountant did not provide services related to the audit or review of American Home Alliance Corp., the former name of~~Hernandez ~~the~~Executive ~~Registrant.~~Chairman

~~During the~~Date: ~~Registrant’s~~July ~~fiscal years ended December 31~~13, ~~2014 and 2013, the subsequent interim period thereto, and through May 9,~~ 2016, there were no “disagreements” (as such term is defined in Item 304 of Regulation S-K) with the Former Accountant on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to the satisfaction of the Former Accountant would have caused them to make reference thereto in their reports on the financial statements for such periods.

During the Registrant’s most recent fiscal year, the subsequent interim period thereto, and through May 9, 2016, there were no “reportable events” (as such term is defined in Item 304 of Regulation S-K).2

Prior to retaining the New Accountant, we did not consult with the New Accountant regarding either: (i) the application of accounting principles to a specified transaction, either contemplated or proposed, or the type of audit opinion that might be rendered on the Registrant’s financial statements; or (ii) any matter that was the subject of a “disagreement” or a “reportable event” (as those terms are defined in Item 304 of Regulation S-K).

On May 11, 2016, the Registrant provided the Former Accountant with its disclosures in this Current Report on Form 8-K disclosing the dismissal of the Former Accountant and requested in writing that the Former Accountant furnish us with a letter addressed to the Securities and Exchange Commission stating whether or not they agree with such disclosures. The Former Accountant’s response is filed as an exhibit to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
16.1	Letter from EisnerAmper, LLP to the Securities and Exchange Commission

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 12, 2016

EMBER THERAPEUTICS, INC. By: /s/ Joseph Hernandez Name: Joseph Hernandez Title: Executive Chairman

Filing Compare · EMBER THERAPEUTICS, INC. - NY